1. bookVolumen 22 (2014): Heft 1 (March 2014)
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
2284-5623
ISSN
2284-5623
Erstveröffentlichung
08 Aug 2013
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch
access type Uneingeschränkter Zugang

Blastic plasmacytoid dendritic cell neoplasia - a rare type of acute leukemia

Online veröffentlicht: 25 Mar 2014
Volumen & Heft: Volumen 22 (2014) - Heft 1 (March 2014)
Seitenbereich: 69 - 77
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
2284-5623
ISSN
2284-5623
Erstveröffentlichung
08 Aug 2013
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), recently classified among the acute myeloid leukemia and related precursor neoplasms, is a rare hematological malignancy with highly aggressive clinical course. We report a case of a 55 year-old female patient who presented spontaneous rupture of the spleen. The histopathological diagnosis without immunohistochemistry was splenic marginal zone non-Hodgkin lymphoma (NHL). The patient received 4 courses of polychemotherapy. Due to the unfavorable evolution the spleen was histopathologically reexamined and immunohistochemistry was performed in another laboratory. The diagnosis of NHL was excluded. Undifferentiated malignant cell proliferation, possible myeloid was suspected. Due to the discrepancy between diagnoses, a third immunohistological examination was performed in a third laboratory. NHL was excluded and myeloid, NK-cell or plasmacytoid dendritic cell leukemia was suspected. The patient was admitted to our clinic after 8 months from the initial diagnosis. Immunophenotyping by flowcytometry from the bone marrow showed 23% blasts positive for CD4, CD56, CD123, HLA-DR, CD38, CD11b, CD2, and negative for lineage specific markers of B-, T-lymphoid, NK- or myelomonocytic cells. The final diagnosis was BPDCN in leukemic phase. Due to the diversity of the clinical presentation, morphology and immunophenotype of BPDCN the diagnosis of this rare malignancy remains challenging. Immunophenotyping by flowcytometry is superior to immunohistochemistry because of the availability of a larger panel of antibodies and the possibility to identify the intensity of antigen expression. The atypical forms of BPDCN should be recognized early in order to manage properly the patients with this aggressive disease

Cuvinte cheie

1. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm in: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. International Agency for Research on Cancer. Lyon 2008;145-7.Search in Google Scholar

2. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol. 2007;136(4):539-48. DOI: 10.1111/j.1365-2141.2006.06458.x10.1111/j.1365-2141.2006.06458.x17367408Search in Google Scholar

3. Lúcio P, Parreira A, Orfao A. CD123hi dendritic cell lymphoma: an unusual case of non-Hodgkin lymphoma. Ann Intern Med. 1999;131(7):549-50. DOI: 10.7326/0003-4819-131-7-199910050-0003510.7326/0003-4819-131-7-199910050-0003510507983Search in Google Scholar

4. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-7. DOI: 10.1182/blood.V97.10.321010.1182/blood.V97.10.3210Search in Google Scholar

5. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmocytoid dendritic cell neoplasm in children: diagnostic feature and clinical presentations. Haematologica. 2010;95(11):1873-9. DOI: 10.3324/haematol.2010.02617910.3324/haematol.2010.026179296690920663945Search in Google Scholar

6. Herling M, Jones D. CD4+/CD56+ Hematodermic Tumor. The features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127(5):687-700. DOI: 10.1309/FY6PK436NBK0RYD410.1309/FY6PK436NBK0RYD417439829Search in Google Scholar

7. Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmocytoid dendritic cell neoplasm. Hematology Meeting Reports. 2009;3(3):1-3.Search in Google Scholar

8. Jacob MC, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8):941-55.Search in Google Scholar

9. Rauh MJ, Rahman F, Good D, Silverman J, Brennan MK, Dimov N, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leuk Res. 2012;36(1):81-6. DOI: 10.1016/j.leukres. 2011.07.033Search in Google Scholar

10. Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-63. DOI: 10.1182/blood.V99.5.155610.1182/blood.V99.5.1556Search in Google Scholar

11. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87. DOI: 10.1097/PAS. 0b013e3181c5e26bSearch in Google Scholar

12. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-75. DOI: 10.1309/GJWNPD8HU5MAJ83710.1309/GJWNPD8HU5MAJ837Search in Google Scholar

13. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al for GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-36. DOI: 10.1111/j.1365-2141.2009.07679.x10.1111/j.1365-2141.2009.07679.x19388928Search in Google Scholar

14. Pangano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al for GIMEMA-ALWP* (Gruppo Italiano Malattie EMatologiche dell’Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-46. DOI: 10.3324/haematol.2012.07264510.3324/haematol.2012.072645356143123065521Search in Google Scholar

15. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-46. DOI: 10.1038/ sj.bmt.170421510.1038/sj.bmt.1704215709194713130309Search in Google Scholar

16. Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250-4. DOI: 10.1016/j.bbmt.2010.12.70610.1016/j.bbmt.2010.12.70621215813Search in Google Scholar

17. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105(3):1256-64. DOI: 10.1182/ blood-2004-06-241610.1182/blood-2004-06-241615388576Search in Google Scholar

18. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.Search in Google Scholar

19. Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009;76(4):237-48. DOI: 10.1002/ cyto.b.2046910.1002/cyto.b.2046919382197Search in Google Scholar

20. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H,et al. NK-cell Tumor Study Group - Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21(5):1032-40. DOI: 10.1093/annonc/mdp41810.1093/annonc/mdp41819850638Search in Google Scholar

21. Di Bona E, Sartori E, Zambello R, Guercini N, Medeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87(3):250-6.Search in Google Scholar

22. Béné MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! Haematologica. 2009;94(7):891-3. DOI: 10.3324/haematol. 2009.007799Search in Google Scholar

23. Dongen JJM, Lhermitte L, Bottcher S, Almeida J, van der Velden VHJ, Flores-Montero J, et al. Euroflow antibody panels for standardized n-dimensional flowcytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-75. DOI: 10.1038/leu.2012.120 10.1038/leu.2012.120343741022552007Search in Google Scholar

Empfohlene Artikel von Trend MD

Planen Sie Ihre Fernkonferenz mit Scienceendo